Urinary tract infections (UTI) are a common problem in postmenopausal women. The incidence is higher in patients with diabetes mellitus (DM) and very often it can be manifested by asymptomatic bacteriuria (ASB) only. The prevalence of ASB is usually correlated with the length of DM and long–term complications, rather than metabolic parameters of DM [1–4]. Furthermore, the estrogen deficiency has essential role in the presence of bacteriuria. Estrogen fuels the proliferation of lactobacillus in the epithelium of the vagina, lowers the pH, and prevents vaginal colonization of Enterobacteriaceae, the main pathogens of the urinary tract [5, 6]. In a meta–analysis of the significance of ASB in diabetes, performed in Finland, it was stated that the point prevalence of ASB was higher in both women and men as well as in children and adolescents with diabetes mellitus compared with healthy control subjects [7].
The efficacy of estrogen (administered either by oral or vaginal route) in the prevention of UTI has been widely described so far. This article offers interesting approach to the problem emphasizing the maintenance of healthy vaginal flora. According to it the problem of ASB should be solved by maintaining the vaginal flora healthy and normal by using local forms of estriolin.
There are many published studies providing information on the modalities for improving the vaginal health using: vaginal cream, estradiol–vaginal ring, and vaginal pessary [8–12]. In the everyday practice we should strive to obtain the optimal solution between using different forms of estrogen and combining it with antibiotic therapy and watchful waiting. It is important to individualize every patient to give them the best care. Every physician dealing with this kind of patient should not forget the possibility of presence of leukoplakia, so to exclude it, a cystoscopy along with external genitalia inspection is highly advised.
References
- 1.Raz R. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. J Infect Dis. 2001;183(Suppl 1):S74–S76. doi: 10.1086/318842. [DOI] [PubMed] [Google Scholar]
- 2.Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, et al. Urinary tract infection among women aged 40–65: behavioral and sexual risk factors. J Clin Epidemiol. 2001;54:710–718. doi: 10.1016/s0895-4356(00)00352-8. [DOI] [PubMed] [Google Scholar]
- 3.Zhanel GG, Nicolle LE, Harding GKM. Prevalence of asymptomatic bacteriuria in women with diabetes mellitus. Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis. 1995;21:316–322. doi: 10.1093/clinids/21.2.316. [DOI] [PubMed] [Google Scholar]
- 4.Jackson SL, Boyko EJ, Scholes D, Abraham L, Gupta K, Fihn SD. Predictors of urinary tract infection after menopause: a prospective study. Am J Med. 2004;117:903–911. doi: 10.1016/j.amjmed.2004.07.045. [DOI] [PubMed] [Google Scholar]
- 5.Iosif CS, Bekassy Z. Prevalence of genitor–urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257–260. doi: 10.3109/00016348409155509. [DOI] [PubMed] [Google Scholar]
- 6.Raz R. Role of estriol therapy for women with recurrent urinary tract infections: advantages and disadvantages. Inf Dis Clin Pract. 1999;8:64–66. [Google Scholar]
- 7.Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta–analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34:230–235. doi: 10.2337/dc10-0421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, et al. Effectiveness of estriol–containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis. 2003;36:1362–1368. doi: 10.1086/374341. [DOI] [PubMed] [Google Scholar]
- 9.Xu R, Wu Y, Hu Y. Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women. Chung–Hua Fu Chan Ko Tsa Chih (Chinese Journal of Obstetrics & Gynecology) 2001;36:531–533. [PubMed] [Google Scholar]
- 10.Kicovic PM, Cortes–Prieto J, Milojević S, Haspels AA, Aljinovic A. The treatment of postmenopausal vaginal atrophy with ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas. 1980;2:275–282. doi: 10.1016/0378-5122(80)90029-8. [DOI] [PubMed] [Google Scholar]
- 11.Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753–756. doi: 10.1056/NEJM199309093291102. [DOI] [PubMed] [Google Scholar]
- 12.Eriksen B. A randomized, open, parallel–group study on the preventive effect of an estradiol–releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180:1072–1079. doi: 10.1016/s0002-9378(99)70597-1. [DOI] [PubMed] [Google Scholar]
